Studies (59) have shown that MET gene amplification can often coexist with other tumor driver genes in NSCLC, such as EGFR and KRAS mutations and ALK and ROS1 fusions, indicating that MET gene amplification may not act as an intrinsic driver factor within tumors. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.